Medeor Therapeutics is developing personalized cellular immunotherapies utilizing mixed chimerism to enable long-lasting immune tolerance in kidney transplant recipients, reducing the need for lifelong immunosuppressant drugs. The company has completed a Phase 3 trial demonstrating improved organ survival rates, with results pending publication in a peer-reviewed journal.
Funding
$18.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Kidney transplant recipients typically require lifelong immunosuppressant drugs to prevent organ rejection, but these drugs have toxic side effects that negatively impact both the recipient and the donated kidney, with a significant percentage of recipients rejecting their graft within 10 years. Achieving long-lasting immune tolerance, where the recipient's body accepts the donor organ without chronic immunosuppression, remains a significant challenge.
Solution
Medeor Therapeutics is developing a personalized cellular immunotherapy approach based on mixed chimerism to induce long-lasting immune tolerance in HLA-matched living donor kidney transplant recipients. Their investigational therapy involves a single infusion of donor and recipient cells, aiming to create a harmonious coexistence of both immune systems within the recipient. This approach seeks to reduce or eliminate the need for lifelong immunosuppressant drugs, potentially improving long-term organ survival and the overall health of transplant recipients. The company has completed a Phase 3 trial demonstrating improved organ survival rates.
Target Audience
The primary target audience includes kidney transplant recipients who receive HLA-matched kidneys from living donors, as well as the medical professionals (transplant surgeons, nephrologists, and immunologists) who manage their care.
Features
- Personalized cellular immunotherapy using mixed chimerism
- Single-infusion approach for inducing immune tolerance
- Targets HLA-matched living donor kidney transplant recipients
- Aims to reduce or eliminate the need for immunosuppressant drugs
- Designed to promote long-lasting organ survival